Evaluation of statin utilisation in tertiary care teaching hospital: An observational prospective study, YSR Kadapa

Journal of Pharmacovigilance and Drug Research Pub Date : 2023-06-01 DOI:10.53411/jpadr.2023.4.2.5

Suchitra Uppicherla, Divya Sree Tadimarri, Nandha Kumar K. N., Haritha Rajaboyna, K. D. Yadavendra Reddy, Gowtham Kumar Reddy Ponnolu, Rajaram Cuddapah, Jeevan Kumar B.

{"title":"Evaluation of statin utilisation in tertiary care teaching hospital: An observational prospective study, YSR Kadapa","authors":"Suchitra Uppicherla, Divya Sree Tadimarri, Nandha Kumar K. N., Haritha Rajaboyna, K. D. Yadavendra Reddy, Gowtham Kumar Reddy Ponnolu, Rajaram Cuddapah, Jeevan Kumar B.","doi":"10.53411/jpadr.2023.4.2.5","DOIUrl":null,"url":null,"abstract":"ABSTRACT;\nIntroduction: Statins are highly preferred drugs in the treatment and prevention of atherosclerotic diseases. Statins usage increased in the last two decades. DUE is a cyclic quality-enhancing procedure in the prescription of drugs. Methods: Our study engaged in compiling various prescribing conditions for statins, assessing their effectiveness and safety, and comparing the lipid profile images of atorvastatin and rosuvastatin. A prospective observational study with the involvement of 150 volunteers The complete data collected is analysed using SAS and Microsoft Excel software. Statistical methods of mean, standard deviation, clinical significance, and Z value are calculated.\nResults: Atorvastatin (20 mg, 40 mg, and 80 mg) and Rosuvastatin (5 mg and 10mg) are widely used in the primary, secondary, and tertiary prevention of atherosclerotic cardiovascular and cerebrovascular problems. Average reduction of LDL and total cholesterol levels to 106.5(SD ±11.04) and 203.53 (SD±94) respectively.\nKey words: Atorvastatin, cardiovascular and cerebrovascular problems, non\nadherence, Re-occurrence, Rosuvastatin.","PeriodicalId":388338,"journal":{"name":"Journal of Pharmacovigilance and Drug Research","volume":"10 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacovigilance and Drug Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53411/jpadr.2023.4.2.5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

ABSTRACT; Introduction: Statins are highly preferred drugs in the treatment and prevention of atherosclerotic diseases. Statins usage increased in the last two decades. DUE is a cyclic quality-enhancing procedure in the prescription of drugs. Methods: Our study engaged in compiling various prescribing conditions for statins, assessing their effectiveness and safety, and comparing the lipid profile images of atorvastatin and rosuvastatin. A prospective observational study with the involvement of 150 volunteers The complete data collected is analysed using SAS and Microsoft Excel software. Statistical methods of mean, standard deviation, clinical significance, and Z value are calculated. Results: Atorvastatin (20 mg, 40 mg, and 80 mg) and Rosuvastatin (5 mg and 10mg) are widely used in the primary, secondary, and tertiary prevention of atherosclerotic cardiovascular and cerebrovascular problems. Average reduction of LDL and total cholesterol levels to 106.5(SD ±11.04) and 203.53 (SD±94) respectively. Key words: Atorvastatin, cardiovascular and cerebrovascular problems, non adherence, Re-occurrence, Rosuvastatin.

查看原文本刊更多论文

评价三级护理教学医院他汀类药物的使用:一项观察性前瞻性研究，YSR Kadapa

摘要:他汀类药物是治疗和预防动脉粥样硬化性疾病的首选药物。他汀类药物的使用在过去二十年中有所增加。DUE是药物处方中一个循环的质量提高程序。方法:本研究编制他汀类药物的各种处方条件，评估其有效性和安全性，比较阿托伐他汀和瑞舒伐他汀的血脂图像。一项有150名志愿者参与的前瞻性观察研究，收集的完整数据使用SAS和Microsoft Excel软件进行分析。计算平均值、标准差、临床显著性和Z值的统计方法。结果:阿托伐他汀(20mg、40mg和80mg)和瑞舒伐他汀(5mg和10mg)广泛应用于动脉粥样硬化性心脑血管疾病的一级、二级和三级预防。LDL和总胆固醇水平平均降低至106.5(SD±11.04)和203.53 (SD±94)。关键词:阿托伐他汀，心脑血管问题，不依从，复发，瑞舒伐他汀

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Pharmacovigilance and Drug Research

自引率

0.00%

发文量